Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Day One Biopharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Day One Biopharmaceuticals, Inc.

DAWN

Day One Biopharmaceuticals, Inc.

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. develops targeted oncology therapies for pediatric and adult cancers. Its core product, tovorafenib, is a brain-penetrant RAF kinase inhibitor targeting RAF-driven tumors, including pediatric low-grade glioma. The company focuses on innovative, first- or best-in-class medicines, leveraging clinical development, strategic partnerships, and licensing to address high unmet medical needs across global markets. Its pipeline includes antibody-drug conjugates and kinase inhibitors for high-impact cancers.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Day One Biopharmaceuticals, Inc.

1
1
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals Reports $155.4M Revenue and $107.3M Net Loss for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals Reports Q3 2025 Financial Results with Increased Product Revenue but Declining Profitability

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals Reports 313.9% Revenue Increase in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals Reports $30.8M Revenue in Q1 2025, Significant Loss Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals Reports Significant Financial Growth, Net Loss Improvement in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments